Health Care [ 11/12 ] | Health Care Technology [ 63/75 ]
NASDAQ | Common Stock
Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide.
The company operates through two segments, Software and Services.
It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.
The company also provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, RENAsym, IPFsym, and MITOsym products.
In addition, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions.
Further, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services.
Additionally, it offers creative and insightful consulting services to support its quantitative systems pharmacology/quantitative systems toxicology modelling.
The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies.
Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Jul 2, 24 | 0.15 Decreased by -25.00% | 0.15 |
| Apr 3, 24 | 0.20 Increased by 0.00% | 0.19 Increased by +5.26% |
| Jan 3, 24 | 0.10 Increased by +66.67% | 0.10 |
| Oct 25, 23 | 0.02 Decreased by -50.00% | 0.18 Decreased by -88.89% |
| Jul 6, 23 | 0.20 Increased by 0.00% | 0.20 |
| Apr 5, 23 | 0.20 Decreased by -4.76% | 0.18 Increased by +11.11% |
| Jan 4, 23 | 0.06 Decreased by -60.00% | 0.09 Decreased by -33.33% |
| Oct 26, 22 | 0.04 Increased by +300.00% | 0.07 Decreased by -42.86% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Feb 29, 24 | 18.30 M Increased by +16.22% | 4.03 M Decreased by -3.47% | Increased by +22.01% Decreased by -16.95% |
| Nov 30, 23 | 14.50 M Increased by +21.20% | 1.95 M Increased by +56.22% | Increased by +13.41% Increased by +28.90% |
| Aug 31, 23 | 15.63 M Increased by +33.19% | 534.00 K Decreased by -44.43% | Increased by +3.42% Decreased by -58.28% |
| May 31, 23 | 16.23 M Increased by +8.52% | 4.01 M Decreased by -1.93% | Increased by +24.69% Decreased by -9.64% |
| Feb 28, 23 | 15.75 M Increased by +6.45% | 4.17 M Decreased by -5.33% | Increased by +26.50% Decreased by -11.06% |
| Nov 30, 22 | 11.96 M Decreased by -3.65% | 1.25 M Decreased by -58.86% | Increased by +10.41% Decreased by -57.30% |
| Aug 31, 22 | 11.73 M Increased by +19.24% | 961.00 K Increased by +215.08% | Increased by +8.19% Increased by +164.25% |
| May 31, 22 | 14.96 M Increased by +17.08% | 4.09 M Increased by +7.92% | Increased by +27.32% Decreased by -7.82% |